Trial Profile
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-4482 in Healthy Participants Inoculated With Experimental Influenza Virus
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Molnupiravir (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 18 Mar 2024 Planned End Date changed from 29 Mar 2024 to 28 Jun 2024.
- 18 Mar 2024 Planned primary completion date changed from 29 Mar 2024 to 28 Jun 2024.
- 28 Aug 2023 Status changed from not yet recruiting to recruiting.